These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 29350486)

  • 21. Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy.
    Simon T; Hero B; Faldum A; Handgretinger R; Schrappe M; Klingebiel T; Berthold F
    BMC Cancer; 2011 Jan; 11():21. PubMed ID: 21244693
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of pain outcomes between two anti-GD2 antibodies in patients with neuroblastoma.
    Anghelescu DL; Goldberg JL; Faughnan LG; Wu J; Mao S; Furman WL; Santana VM; Navid F
    Pediatr Blood Cancer; 2015 Feb; 62(2):224-228. PubMed ID: 25382742
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination therapy with interleukin-2 and antitumor monoclonal antibodies.
    Sondel PM; Hank JA
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S121-7. PubMed ID: 9457407
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systemic interleukin-2 modulates the anti-idiotypic response to chimeric anti-GD2 antibody in patients with melanoma.
    Albertini MR; Gan J; Jaeger P; Hank JA; Storer B; Schell K; Rivest T; Surfus J; Reisfeld RA; Schiller JH; Sondel PM
    J Immunother Emphasis Tumor Immunol; 1996 Jul; 19(4):278-95. PubMed ID: 8877722
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies.
    Parsons K; Bernhardt B; Strickland B
    Ann Pharmacother; 2013 Feb; 47(2):210-8. PubMed ID: 23386066
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fenretinide sensitizes multidrug-resistant human neuroblastoma cells to antibody-independent and ch14.18-mediated NK cell cytotoxicity.
    Shibina A; Seidel D; Somanchi SS; Lee DA; Stermann A; Maurer BJ; Lode HN; Reynolds CP; Huebener N
    J Mol Med (Berl); 2013 Apr; 91(4):459-72. PubMed ID: 23052481
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD
    Siebert N; Zumpe M; Jüttner M; Troschke-Meurer S; Lode HN
    Oncoimmunology; 2017; 6(10):e1343775. PubMed ID: 29123953
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma.
    Seidel D; Shibina A; Siebert N; Wels WS; Reynolds CP; Huebener N; Lode HN
    Cancer Immunol Immunother; 2015 May; 64(5):621-34. PubMed ID: 25711293
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative pharmacokinetics, safety, and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapy.
    Marachelian A; Desai A; Balis F; Katzenstein H; Qayed M; Armstrong M; Neville KA; Cohn SL; Bush M; Gunawan R; Lim AP; Smith MA; Smith LM
    Cancer Chemother Pharmacol; 2016 Feb; 77(2):405-12. PubMed ID: 26791869
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of IL-2 on Treatment Tolerance in Patients With High-Risk Neuroblastoma Treated With Dinutuximab Beta-Based Immunotherapy.
    Cicek F; Troschke-Meurer S; Ceylan K; Jahns LJ; Zumpe M; Siebert N; Ehlert K; Lode HN
    Front Pediatr; 2020; 8():582820. PubMed ID: 33392114
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-GD2 immunotherapy for neuroblastoma.
    Sait S; Modak S
    Expert Rev Anticancer Ther; 2017 Oct; 17(10):889-904. PubMed ID: 28780888
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I trial of combined treatment with ch14.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma.
    Choi BS; Sondel PM; Hank JA; Schalch H; Gan J; King DM; Kendra K; Mahvi D; Lee LY; Kim K; Albertini MR
    Cancer Immunol Immunother; 2006 Jul; 55(7):761-74. PubMed ID: 16187086
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ocular symptoms in children treated with human-mouse chimeric anti-GD2 mAb ch14.18 for neuroblastoma.
    Kremens B; Hero B; Esser J; Weinel P; Filger-Brillinger J; Fleischhack G; Graf N; Grüttner HP; Niemeyer C; Schulz A; Wickmann L; Berthold F
    Cancer Immunol Immunother; 2002 Apr; 51(2):107-10. PubMed ID: 11904735
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of interleukin-2, all-trans retinoic acid, and natural killer cells: surveillance mechanisms in anti-GD2 antibody therapy in neuroblastoma.
    Nguyen R; Houston J; Chan WK; Finkelstein D; Dyer MA
    Cancer Immunol Immunother; 2018 Apr; 67(4):615-626. PubMed ID: 29327110
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients.
    Albertini MR; Hank JA; Schiller JH; Khorsand M; Borchert AA; Gan J; Bechhofer R; Storer B; Reisfeld RA; Sondel PM
    Clin Cancer Res; 1997 Aug; 3(8):1277-88. PubMed ID: 9815810
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032.
    Yu AL; Gilman AL; Ozkaynak MF; Naranjo A; Diccianni MB; Gan J; Hank JA; Batova A; London WB; Tenney SC; Smith M; Shulkin BL; Parisi M; Matthay KK; Cohn SL; Maris JM; Bagatell R; Park JR; Sondel PM
    Clin Cancer Res; 2021 Apr; 27(8):2179-2189. PubMed ID: 33504555
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular characterization of the anti-idiotypic immune response of a relapse-free neuroblastoma patient following antibody therapy: a possible vaccine against tumors of neuroectodermal origin?
    Uttenreuther-Fischer MM; Krüger JA; Fischer P
    J Immunol; 2006 Jun; 176(12):7775-86. PubMed ID: 16751426
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bone marrow minimal residual disease was an early response marker and a consistent independent predictor of survival after anti-GD2 immunotherapy.
    Cheung NK; Ostrovnaya I; Kuk D; Cheung IY
    J Clin Oncol; 2015 Mar; 33(7):755-63. PubMed ID: 25559819
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Humanized 3F8 Anti-GD2 Monoclonal Antibody Dosing With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Resistant Neuroblastoma: A Phase 1 Clinical Trial.
    Kushner BH; Cheung IY; Modak S; Basu EM; Roberts SS; Cheung NK
    JAMA Oncol; 2018 Dec; 4(12):1729-1735. PubMed ID: 30326045
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group.
    Frost JD; Hank JA; Reaman GH; Frierdich S; Seeger RC; Gan J; Anderson PM; Ettinger LJ; Cairo MS; Blazar BR; Krailo MD; Matthay KK; Reisfeld RA; Sondel PM
    Cancer; 1997 Jul; 80(2):317-33. PubMed ID: 9217046
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.